Aurora Cannabis (TSE:ACB) had its price objective cut by CIBC from C$27.00 to C$14.00 in a research note published on Tuesday morning, BayStreet.CA reports.
ACB has been the subject of a number of other research reports. Canaccord Genuity reduced their price objective on Aurora Cannabis from C$3.00 to C$2.25 in a research report on Friday, February 14th. Jefferies Financial Group reduced their price objective on Aurora Cannabis from C$1.90 to C$1.00 in a research report on Thursday, April 16th. MKM Partners boosted their price objective on Aurora Cannabis from C$12.00 to C$18.00 in a research report on Tuesday. Cowen cut their target price on Aurora Cannabis from C$12.00 to C$11.00 in a research note on Monday. Finally, Pi Financial set a C$2.00 target price on Aurora Cannabis and gave the company a neutral rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. Aurora Cannabis has a consensus rating of Hold and a consensus price target of C$10.08.
TSE:ACB opened at C$24.10 on Tuesday. Aurora Cannabis has a 12-month low of C$7.50 and a 12-month high of C$141.00. The firm has a market capitalization of $1.97 billion and a P/E ratio of -18.50. The company has a debt-to-equity ratio of 15.75, a current ratio of 2.94 and a quick ratio of 1.26. The business has a 50 day simple moving average of C$3.58 and a 200 day simple moving average of C$2.88.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Featured Article: What is Elliott Wave theory?